Toxic multinodular goiter is a condition in which an enlarged thyroid gland containing multiple nodules produces excess thyroid hormone on its own, independent of the brain’s normal signaling. It is one of the most common causes of hyperthyroidism, particularly in older adults and in regions where dietary iodine has historically been low. Unlike Graves’ disease, which is driven by the immune system attacking the thyroid, toxic multinodular goiter arises from mutations within the nodules themselves that cause them to churn out hormone autonomously. The condition develops gradually over years, which makes it both easy to miss and surprisingly consequential by the time it is caught.
What Is Happening Inside the Thyroid
A normal thyroid gland responds to a hormone called TSH, produced by the pituitary gland in the brain. When the body needs more thyroid hormone, TSH rises; when it has enough, TSH falls. The thyroid obeys that signal. In toxic multinodular goiter, certain nodules stop listening. They produce thyroid hormone regardless of what TSH tells them to do.
The reason traces to somatic mutations in the TSH receptor gene. Research has found that the vast majority of the overactive nodules in toxic multinodular goiters carry mutations that lock the TSH receptor into an “on” position, causing the cell to behave as though it is constantly being stimulated even when TSH levels are actually suppressed. One study found these activating mutations in five out of six hyperfunctioning nodules examined, and confirmed that they were the same type of mutations found in solitary toxic adenomas, a related but simpler condition involving a single overactive nodule.1PubMed. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma Separate work confirmed that constitutively activating mutations of the TSH receptor are a frequent molecular driver in both solitary toxic nodules and toxic multinodular goiters.2The Journal of Clinical Endocrinology & Metabolism. Identification of Constitutively Activating Somatic Thyrotropin Receptor Mutations in a Subset of Toxic Multinodular Goiters
What this means practically is that the disease is not a sudden event. A person may carry a nontoxic multinodular goiter for decades before one or more nodules accumulate enough mutations to become autonomous. The transition from “lumpy thyroid that works fine” to “lumpy thyroid that overproduces hormone” is slow and often clinically silent in its early stages.
Who Gets It and Why Iodine Matters
Toxic multinodular goiter is overwhelmingly a condition of middle-aged and older adults. Most patients diagnosed are over 50. The condition is also significantly more common in parts of the world with low iodine intake, a pattern that has been well documented by comparing populations with different iodine levels. A comparative study of East Jutland, Denmark (historically mild iodine deficiency) and Iceland (adequate iodine intake) found that hyperthyroidism was substantially more common in the Danish population, driven almost entirely by higher rates of toxic multinodular goiter and solitary toxic adenomas. Most of those patients were elderly.3PubMed. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area
The mechanism is straightforward: iodine deficiency stimulates the thyroid to grow, which over time produces nodules. The longer the gland is enlarged and nodular, the greater the chance that one or more nodules develop the autonomy-conferring mutations described above. In iodine-sufficient countries, Graves’ disease tends to dominate as the leading cause of hyperthyroidism. In iodine-deficient regions, toxic nodular goiter takes the lead, especially in older populations.4PubMed. Toxic multinodular goiter in the elderly
Women are affected more often than men, consistent with thyroid disease in general. Family history of goiter is also a risk factor, though the genetic contribution is less sharply defined than in Graves’ disease. Smoking has been linked to goiter growth independent of iodine status.
Symptoms That Are Easy to Blame on Aging
One of the trickiest aspects of toxic multinodular goiter is that its symptoms overlap heavily with ordinary aging complaints, particularly in the elderly patients who are most likely to have it. The classic features of hyperthyroidism include a fast or irregular heartbeat, unintentional weight loss, heat intolerance, tremor, anxiety, and frequent bowel movements. In younger patients with Graves’ disease, these tend to be dramatic and unmistakable.
In older adults with toxic multinodular goiter, the presentation is often far more muted. Some patients develop what is called apathetic hyperthyroidism, where instead of feeling anxious and wired, they seem withdrawn, fatigued, or even depressed. The heart may be the only organ shouting, presenting as new-onset atrial fibrillation or worsening heart failure while the patient otherwise looks calm.5BMJ Best Practice. Toxic multinodular goitre Others may have subclinical hyperthyroidism, where the TSH is suppressed on a blood test but thyroid hormone levels are still in the normal range, causing no obvious symptoms at all.
This makes the condition easy to miss. A 70-year-old with new atrial fibrillation, modest weight loss, and fatigue may get worked up for heart disease and never have their thyroid checked. Or they may be told that “your thyroid is a little off” without anyone investigating further. The insidious onset means many patients have been mildly hyperthyroid for years before diagnosis.
Telling It Apart from Graves’ Disease
Distinguishing toxic multinodular goiter from Graves’ disease matters because the two conditions have different causes, different natural histories, and sometimes call for different treatment strategies. The overlap can be confusing because some patients with multinodular goiters also have Graves’ disease layered on top, creating a mixed picture.
Clinicians use a combination of blood tests and imaging to sort this out. Thyroid antibodies, specifically TSH-receptor antibodies, point toward Graves’ disease. A radioiodine uptake scan shows diffuse, even uptake across the gland in Graves’ but patchy, focal uptake in distinct nodules in toxic multinodular goiter. Ultrasound with Doppler can also help: one study found that patients whose multinodular goiters showed diffuse blood flow patterns and positive autoantibodies were likely dealing with the multinodular variant of Graves’ disease, while those with localized uptake in discrete nodules and no autoimmunity had true non-autoimmune toxic multinodular goiter.6European Journal of Endocrinology. The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres
This distinction is more than academic. Graves’ disease can go into remission after a course of antithyroid medication, making a trial of drugs a reasonable first step. True toxic multinodular goiter essentially never remits on its own. The autonomous nodules will keep producing hormone as long as they exist, which means definitive treatment, either radioiodine or surgery, is usually needed at some point.
Cardiovascular Risk and Bone Loss
The excess thyroid hormone produced by toxic multinodular goiter takes a real toll on the cardiovascular system. Thyroid hormone speeds up the heart, increases blood pressure, and can trigger atrial fibrillation. Over time, it strains the heart muscle and worsens outcomes in people with preexisting heart disease. A large study comparing outcomes across different types of hyperthyroidism found that cardiovascular morbidity and mortality were notably elevated in patients treated for toxic nodular goiter compared to those with Graves’ disease or nontoxic goiter.7PubMed. Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves’ Disease and Nontoxic Goiter
The reasons for the worse outcomes in toxic multinodular goiter compared to Graves’ disease probably reflect the patient population: these tend to be older patients with a longer duration of undiagnosed hyperthyroidism. Their hearts have been exposed to excess thyroid hormone for years before anyone intervened. This is one of the strongest arguments for taking even mild TSH suppression seriously in an older adult with a nodular thyroid.
Bone is also affected. Thyroid hormone accelerates bone turnover, and sustained excess can reduce bone density. A study of elderly patients with toxic nodular goiter found reduced bone mineral density at both the spine and hip, underscoring that bone health screening deserves attention in this group.8PubMed. Bone mineral density in geriatric patients with toxic nodular goiter
The Question of Cancer in Hyperfunctioning Glands
There is a longstanding belief that hyperfunctioning thyroid tissue is unlikely to harbor cancer, because autonomous nodules tend to be well-differentiated and benign. This is mostly true, but “mostly” is not “always.” Data from surgical series at the Mayo Clinic found occult malignancies in roughly two to three percent of thyroidectomy specimens removed for toxic multinodular goiter.9PubMed Central. Evidence-based management of toxic multinodular goiter (Plummer’s Disease)
That number is low enough that routine cancer concern is not warranted for every patient, but high enough that suspicious nodules should not be ignored simply because the gland is hyperfunctioning. Ultrasound-guided fine-needle aspiration biopsy is valuable in this setting, particularly for nodules larger than about five millimeters that have worrisome features on imaging.10PubMed. Thyroid cancer in hyperthyroidism: incidence rates and value of ultrasound-guided fine-needle aspiration biopsy in this patient group This is especially relevant when surgery is being considered anyway, or when radioiodine treatment might destroy the chance to biopsy later.
Treatment with Antithyroid Medication
Antithyroid drugs such as methimazole work by blocking the production of thyroid hormone. In toxic multinodular goiter, these medications can effectively control hormone levels, but they do not shrink the goiter or eliminate the autonomous nodules. Once the drug is stopped, the hyperthyroidism returns. This makes long-term medication a management strategy rather than a cure.
That said, long-term methimazole has some real advantages. A study comparing long-term methimazole to radioiodine over a 12-year follow-up found that patients on methimazole achieved euthyroidism (normal thyroid levels) faster, on average about four months versus over 16 months for radioiodine. Methimazole patients also spent a much larger proportion of the study period in a euthyroid state, roughly 96% of the time versus about 72% in the radioiodine group. And hypothyroidism, the opposite problem of an underactive thyroid, occurred in only about 4% of the methimazole group compared to 46% of the radioiodine group.11Korean Endocrinology Society. Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in the Treatment of Toxic Multinodular Goiter
The downside is that the patient has to take pills indefinitely and undergo regular blood monitoring. Methimazole also carries rare but serious side effects, including a drop in white blood cells and liver problems. For patients who are not good candidates for surgery or radioiodine, perhaps because of age or other medical conditions, long-term low-dose methimazole is a perfectly reasonable choice.
Radioiodine Therapy
Radioiodine (iodine-131) is the most widely used definitive treatment for toxic multinodular goiter in many countries. The radioactive iodine is swallowed as a capsule or liquid, concentrates in thyroid tissue, and destroys the overactive cells from within. It is nonsurgical, does not require anesthesia, and has decades of safety data behind it.
One large series found that one or two treatments cured about 92% of patients, with roughly half achieving normal thyroid levels within three months of their first dose. The median thyroid volume shrank by about 43% over 24 months.12PubMed. Radioiodine therapy for multinodular toxic goiter These are good numbers, but a few things are worth noting. Very large goiters may need more than one dose. The shrinkage, while real, may not be enough to relieve compressive symptoms in patients whose primary complaint is a goiter pressing on the windpipe or esophagus. And as the methimazole comparison study showed, a substantial proportion of patients end up hypothyroid after radioiodine, which simply trades one lifelong medication (antithyroid drugs) for another (thyroid hormone replacement).
For many older patients who want a one-and-done treatment and do not have a very large goiter, radioiodine remains the standard approach. It avoids surgical risk entirely, which is a meaningful consideration in a population where heart disease and other comorbidities are common.
When Surgery Makes Sense
Total thyroidectomy, removing the entire thyroid gland, is the most definitive treatment for toxic multinodular goiter. It eliminates the source of excess hormone immediately, removes any cancer risk within the gland, and relieves compressive symptoms if the goiter is large enough to press on the airway or swallowing structures. There is no risk of recurrence because there is no thyroid left to recur.
The trade-off is surgical risk. Total thyroidectomy carries a real chance of hypoparathyroidism (damage to the parathyroid glands, which control calcium) and injury to the recurrent laryngeal nerve, which controls the vocal cords. In a prospective study of nearly 300 patients undergoing total thyroidectomy for multinodular goiter at an experienced center, temporary complications appeared in about 21% of cases, but permanent complications were rare at roughly 1%, comprising two cases of permanent hypoparathyroidism and one case of permanent nerve injury. There were no deaths.13PubMed Central. Prospective Study of Postoperative Complications After Total Thyroidectomy for Multinodular Goiters by Surgeons With Experience in Endocrine Surgery
Surgeon experience matters enormously here. The complication rates above come from a high-volume endocrine surgery center. At less experienced centers, permanent complication rates can be higher. Total thyroidectomy is generally preferred over partial removal because leaving thyroid tissue behind allows the disease to recur, though some surgeons still consider less-than-total approaches in selected patients when the nodular disease is clearly one-sided.14PubMed Central. Less than total thyroidectomy for goiter: when and how?
Surgery is typically the first-line recommendation when the goiter is large and causing compressive symptoms, when there is a suspicion of cancer based on biopsy results, or when the patient cannot tolerate or does not want radioiodine. After total thyroidectomy, patients take thyroid hormone replacement permanently.
Radiofrequency Ablation and Other Newer Approaches
For patients who are not ideal candidates for surgery or radioiodine, or who want to avoid both, radiofrequency ablation has emerged as an option. This technique uses a needle-like probe guided by ultrasound to deliver heat directly into the overactive nodule, destroying it without removing the gland. It is performed under local anesthesia, usually as an outpatient procedure. Early data suggest it can control hyperthyroidism in selected patients, particularly those with a limited number of dominant autonomous nodules rather than a diffusely nodular gland.15PubMed Central. Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success
The appeal is obvious: no general anesthesia, no lifelong hypothyroidism, no radiation exposure. But the evidence is still maturing. Radiofrequency ablation works best for discrete, well-defined nodules, and toxic multinodular goiter by definition involves multiple nodules. In patients with only one or two dominant hot nodules driving the hyperthyroidism, ablation may be a reasonable middle ground. For patients with many autonomous nodules throughout the gland, the technique’s limitations become apparent.
Compressive Symptoms and Large Goiters
Some toxic multinodular goiters grow large enough to cause mechanical problems independent of the hormone excess. The thyroid sits just in front of the trachea and alongside the esophagus, so a significantly enlarged gland can compress the airway, making breathing difficult, or press on the esophagus, making swallowing uncomfortable. Some goiters extend downward behind the breastbone, a configuration called substernal or retrosternal goiter, which can cause additional complications including compression of blood vessels returning to the heart.
When compressive symptoms are present, surgery is almost always the preferred treatment. Radioiodine can shrink the gland over months, but the reduction may not be sufficient or fast enough for someone who is already having trouble breathing. Large substernal goiters also pose challenges for radioiodine because the tissue behind the sternum may not take up iodine as efficiently. Surgical removal of a large multinodular goiter is more complex than removing a normal-sized gland, and may require a more experienced surgical team, but it provides immediate relief of compressive symptoms.
Subclinical Disease and When to Treat
Many patients with toxic multinodular goiter are first identified when a routine blood test shows a low TSH with normal thyroid hormone levels. This is subclinical hyperthyroidism, and the question of whether to treat it is genuinely debated. The patient feels fine. Their thyroid hormones are technically in range. Why intervene?
The argument for treatment rests on the downstream consequences. Even mild, sustained TSH suppression in an older adult has been linked to increased risk of atrial fibrillation and accelerated bone loss. Unlike subclinical hyperthyroidism from Graves’ disease, which may spontaneously resolve, subclinical disease from toxic multinodular goiter almost never reverses on its own. The autonomous nodules will continue producing hormone, and many patients will progress to overt hyperthyroidism over time. Current guidelines generally recommend treatment for subclinical hyperthyroidism in patients over 65, or in younger patients with heart disease, osteoporosis, or symptoms. For younger, otherwise healthy patients with mildly suppressed TSH, watchful waiting with periodic blood tests is reasonable.
Why the Name “Plummer’s Disease” Persists
You may encounter toxic multinodular goiter referred to as Plummer’s disease, after Henry Plummer, a physician at the Mayo Clinic in the early twentieth century who distinguished it from Graves’ disease. The term is still used informally in some clinical settings, though it is somewhat ambiguous: some use it specifically for toxic multinodular goiter, while others apply it more broadly to any autonomous thyroid nodule, including solitary toxic adenomas. The historical importance of Plummer’s work was in recognizing that not all hyperthyroidism is autoimmune. The Mayo Clinic continued to be a major referral center for this condition; between 1950 and 2006, roughly 70% of their patients with Plummer’s disease were treated surgically.16PubMed Central. Evidence-based management of toxic multinodular goiter (Plummer’s Disease) That surgical preference has shifted in many places as radioiodine and long-term medical therapy have become more common, but it reflects the era when surgery was the only reliable definitive option.